ABUS
Arbutus Biopharma Corporation
Set alert
- YTD
- -12.47%
- 1 year
- -13.02%
- Open
- 4.28
- Prev close
- 4.28
- Mkt cap
- 645.29M
- Vol
- 2.53M
- Avg vol
- 4.88M
- EPS
- 0.79
- P/E
- 5.33
- Div yield
- 0.00%
More statistics
- Low
- 4.14
- High
- 4.30
- Forward P/E
- -30.67
- Beta
- 0.62
- Short ratio
- 5.03
- Inst. own
- 72.71%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 16, 2026
- 50-d avg
- 4.79
- 200-d avg
- 4.52
- 1y target
- 5.46
Discussion (236)
Sign in to join the discussion
We want the cancer cure and the fast track gets us closer.
Pretty good chunk of more cash
At least we can confirm we got more cash on the way.
Bizzaro blocking on basic shit
…as a reference point. They used it.
Its the conclusion of how you got to and endpoint without a patent. If they used a patent as a reference point. They used it in my opinion.
Last time we checked we wanted the shit to work. Why didn’t you use the patents?
Was there a compelling reason to not use the patents available to them? What efforts did they make to justify not using proven technology and what scientific justification did they come to not use the patents that were available?
Why couldn’t they just collaborate and support the scientific process? They took ABUS work and maliciously used it without regard to the science they actually paid for.
The same ones they licensed. No null hypothesis. It will be easy to show they copied and pasted with no scientific process to alter proven patents they used.